Home / World Marketplace / Archive by category Global Health & Biotech (Page 28)

Archive by category Global Health & Biotech

Carestream Launches Carestream 360º: A New Analytics Dashboard for Streamlined Reporting and Deeper Operational Insight

Rochester, N.Y., May 21, 2025 (Korea Bizwire) — Carestream Health today announced the U.S. market launch of Carestream 360º, an advanced analytics dashboard designed to help radiology departments track key performance metrics, analyze imaging trends, and optimize operational efficiency. Carestream 360º automatically collects data from connected Carestream Digital Radiography (DR) systems, consolidating it into a [...]

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia, May 21, 2025 (Korea Bizwire) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will participate in the following upcoming investor conferences: Jefferies Global Healthcare [...]

Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals

Global supply of technetium-99m, most widely used medical isotopes in nuclear medicine, is secured for the coming years PETTEN, The Netherlands, May 21, 2025 (Korea Bizwire) — NRG PALLAS and Curium have extended their collaboration to produce molybdenum-99 through a new multi-year agreement. Molybdenum-99, which transforms into technetium-99, is a critical isotope used in nuclear [...]

Teva Announces Successful Upsizing and Pricing of $2,300,000,000 (Equivalent) Senior Notes; Proceeds to Repay Existing Debt

TEL AVIV, Israel, May 20, 2025 (Korea Bizwire) – Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “Notes”). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects [...]

Fitch Ratings Agency Upgrades Teva Rating to BB+ Recognizing Successful Execution of Its Pivot to Growth Strategy

TEL AVIV, Israel, May 20, 2025 (Korea Bizwire) – Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company’s corporate credit rating to BB+, with a stable outlook; from BB. Fitch’s report cites Teva’s progress in reducing debt and improving flexibility, expects continuous revenue growth from AUSTEDO and AJOVY, [...]

Medela Introduces Magic InBra™ With FluidFeel Technology™—Where Science Meets Uncompromising Care

Six Decades of Lactation Research Culminate in the Company’s Latest Innovation That Unites Powerful Performance With Supreme Gentleness Baar, Switzerland, May 20, 2025 (Korea Bizwire) – Research-Driven Innovation Highlights: FluidFeel Technology™: Developed through extensive lactation research, this feature creates an optimized pumping environment by allowing warm milk circulation around the nipple—a condition clinically shown to enhance milk [...]

Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures

May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation 824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the US Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader [...]

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

Company’s first development candidate in autoimmune and inflammatory disease (AIID) demonstrates potent blockade of IL-4, IL-13, and IL-33 signaling pathways critical in respiratory inflammation Novel bispecific design shows promising potential manufacturability and stability to support high dosing concentration and subcutaneous administration Regulatory filing to support Phase 1 studies expected in 2H-2026 VANCOUVER, British Columbia, May [...]

Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation rates to placebo

Nerandomilast, an investigational agent, met the primary endpoint of both phase III trials, FIBRONEER™-IPF and FIBRONEER™-ILD, significantly reducing the decline in forced vital capacity (FVC) [mL] by absolute change from baseline at week 52, compared to placebo.1,2 Nerandomilast’s safety and tolerability profile was consistent across both trials, with similar rates of permanent treatment discontinuation to [...]

Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031

TEL AVIV, Israel, May 19, 2025 (Korea Bizwire) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today that it has commenced tender offers (the “Offers”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the “Total Maximum Amount”) of the following series [...]